CD56 bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: The Canadian blood and marrow transplant group randomized 0601 study results

Amina Kariminia, Sabine Ivison, Bernard Ng, Jacob Rozmus, Susanna Sung, Avani Varshney, Mahmoud Aljurf, Sylvie Lachance, Irwin Walker, Cindy Toze, Jeff Lipton, Stephanie J. Lee, Jeff Szer, Richard Doocey, Ian Lewis, Clayton Smith, Naeem Chaudhri, Megan K. Levings, Raewyn Broady, Gerald DevinsDavid Szwajcer, Ronan Foley, Sara Mostafavi, Steven Pavletic, Donna A. Wall, Stephan Couban, Tony Panzarella, Kirk R. Schultz

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)

Abstract

Randomized trials have conclusively shown higher rates of chronic graft-versus-host disease with filgrastim-stimulated apheresis peripheral blood as a donor source than unstimulated bone marrow. The Canadian Blood and Marrow Transplant Group conducted a phase 3 study of adults who received either filgrastim-stimulated apheresis peripheral blood or filgrastim-stimulated bone marrow from human leukocyte antigen-identical sibling donors. Because all donors received the identical filgrastim dosing schedule, this study allowed for a controlled evaluation of the impact of stem cell source on development of chronic graft-versus-host disease. One hundred and twenty-one evaluable filgrastim-stimulated apheresis peripheral blood and filgrastim-stimulated bone marrow patient donor products were immunologically characterized by flow cytometry and tested for their association with acute and chronic graft-versus-host disease within 2 years of transplantation. The immune populations evaluated included, regulatory T cells, central memory and effector T cells, interferon γ positive producing T cells, invariate natural killer T cells, regulatory natural killer cells, dendritic cell populations, macrophages, and activated B cells and memory B cells. When both filgrastim-stimulated apheresis peripheral blood and filgrastimstimulated bone marrow were grouped together, a higher chronic graftversus- host disease frequency was associated with lower proportions of CD56 bright natural killer regulatory cells and interferon γ-producing T helper cells in the donor product. Lower CD56 bright natural killer regulatory cells displayed differential impacts on the development of extensive chronic graft-versus-host disease between filgrastim-stimulated apheresis peripheral blood and filgrastim-stimulated bone marrow. In summary, while controlling for the potential impact of filgrastim on marrow, our studies demonstrated that CD56 bright natural killer regulatory cells had a much stronger impact on filgrastim-stimulated apheresis peripheral blood than on filgrastim-stimulated bone marrow. This supports the conclusion that a lower proportion of CD56 bright natural killer regulatory cells results in the high rate of chronic graft-versus-host disease seen in filgrastim-stimulated apheresis peripheral blood. clinicaltrials.gov Identifier: 00438958.peripheral blood and filgrastim-stimulated bone marrow. In summary, while controlling for the potential impact of filgrastim on marrow, our studies demonstrated that CD56 bright natural killer regulatory cells had a much stronger impact on filgrastim-stimulated apheresis peripheral blood than on filgrastim-stimulated bone marrow. This supports the conclusion that a lower proportion of CD56 bright natural killer regulatory cells results in the high rate of chronic graft-versus-host disease seen in filgrastim-stimulated apheresis peripheral blood. clinicaltrials.gov Identifier: 00438958.

Original languageEnglish
Pages (from-to)1936-1946
Number of pages11
JournalHaematologica
Volume102
Issue number11
DOIs
Publication statusPublished - Oct 27 2017

Bibliographical note

Funding Information:
This study was undertaken by the CBMTG and funded by a grant from the United States National Cancer Institute (Principal Investigator: K.R. Schultz; Grant 1R01CA108752-01A2) and CBMTG. We gratefully acknowledge the recipients, donors and staff of the BMT Programs who participated in this study.

Publisher Copyright:
© 2017 Ferrata Storti Foundation.

ASJC Scopus Subject Areas

  • Hematology

PubMed: MeSH publication types

  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'CD56 bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: The Canadian blood and marrow transplant group randomized 0601 study results'. Together they form a unique fingerprint.

Cite this